Christine I Chen

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes
    C I Chen
    University of Toronto Autologous Bone Marrow Transplant Program, The Princess Margaret Hospital, Ontario, Canada
    Bone Marrow Transplant 27:177-82. 2001
  2. ncbi Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia
    Christine I Chen
    Princess Margaret Hospital Ontario Cancer Institute, Toronto, Ontario, Canada
    J Clin Oncol 29:1175-81. 2011
  3. ncbi Bortezomib in relapsed or refractory Waldenström's macroglobulinemia
    Christine Chen
    Princess Margaret Hospital, Toronto, Ontario, Canada
    Clin Lymphoma Myeloma 9:74-6. 2009
  4. ncbi Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group
    Christine I Chen
    Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 25:1570-5. 2007
  5. ncbi Sequential, cycling maintenance therapy for post transplant multiple myeloma
    C I Chen
    Department of Haematology Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Bone Marrow Transplant 37:89-94. 2006
  6. ncbi Treatment for Waldenstrom's macroglobulinemia
    C I Chen
    Princess Margaret Hospital Ontario Cancer Institute, Toronto, Ontario, Canada
    Ann Oncol 15:550-8. 2004
  7. ncbi Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant
    A Keith Stewart
    Princess Margaret Hospital, Toronto, Ontario, Canada
    Clin Cancer Res 10:8170-6. 2004
  8. ncbi Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation
    Young Trieu
    Department of Medical Oncology/Hematolog, Princess Margaret Hospital, University Health Network, Toronto, Ontario
    Mayo Clin Proc 80:1578-82. 2005
  9. ncbi 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma
    C I Chen
    The University of Toronto Autologous Blood and Marrow Transplant Program, Princess Margaret Hospital, University Health Network, Toronto, Canada
    Bone Marrow Transplant 30:885-91. 2002
  10. ncbi The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant
    Hong Chang
    Department of Laboratory Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada
    Br J Haematol 125:64-8. 2004

Collaborators

Detail Information

Publications12

  1. ncbi Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes
    C I Chen
    University of Toronto Autologous Bone Marrow Transplant Program, The Princess Margaret Hospital, Ontario, Canada
    Bone Marrow Transplant 27:177-82. 2001
    ..We conclude that radiation-associated pneumonitis cannot be easily predicted by pretransplant variables. Therefore surveillance, early recognition and prompt therapy are recommended...
  2. ncbi Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia
    Christine I Chen
    Princess Margaret Hospital Ontario Cancer Institute, Toronto, Ontario, Canada
    J Clin Oncol 29:1175-81. 2011
    ..Based on encouraging reports of lenalidomide in relapsed and refractory chronic lymphocytic leukemia (CLL), we investigated the first-line use of single-agent lenalidomide in CLL...
  3. ncbi Bortezomib in relapsed or refractory Waldenström's macroglobulinemia
    Christine Chen
    Princess Margaret Hospital, Toronto, Ontario, Canada
    Clin Lymphoma Myeloma 9:74-6. 2009
    ..Bortezomib-based combination therapies, with consideration for attenuated or intermittent dosing of bortezomib to minimize neuropathy, are under investigation...
  4. ncbi Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group
    Christine I Chen
    Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 25:1570-5. 2007
    ..To evaluate the efficacy and toxicity of single-agent bortezomib in Waldenström's macroglobulinemia (WM)...
  5. ncbi Sequential, cycling maintenance therapy for post transplant multiple myeloma
    C I Chen
    Department of Haematology Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Bone Marrow Transplant 37:89-94. 2006
    ..This concept of cycling, sequential maintenance with various agents, perhaps including newer biological, targeted agents, warrants further investigation in multiple myeloma...
  6. ncbi Treatment for Waldenstrom's macroglobulinemia
    C I Chen
    Princess Margaret Hospital Ontario Cancer Institute, Toronto, Ontario, Canada
    Ann Oncol 15:550-8. 2004
    ..Choices range from biological agents to combination chemotherapy to stem-cell transplantation. A rational approach therefore must be based on careful patient assessment and individualization of therapy...
  7. ncbi Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant
    A Keith Stewart
    Princess Margaret Hospital, Toronto, Ontario, Canada
    Clin Cancer Res 10:8170-6. 2004
    ....
  8. ncbi Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation
    Young Trieu
    Department of Medical Oncology/Hematolog, Princess Margaret Hospital, University Health Network, Toronto, Ontario
    Mayo Clin Proc 80:1578-82. 2005
    ..6 months (95% CI, 22.1-not available months). CONCLUSION: Our data show that CP is an effective, well-tolerated, and convenient regimen as salvage therapy for MM after ASCT...
  9. ncbi 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma
    C I Chen
    The University of Toronto Autologous Blood and Marrow Transplant Program, Princess Margaret Hospital, University Health Network, Toronto, Canada
    Bone Marrow Transplant 30:885-91. 2002
    ..We conclude that high-dose therapy with ABMT is appropriate for lymphoma patients even when disease reduction requires repeated numbers of salvage regimens...
  10. ncbi The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant
    Hong Chang
    Department of Laboratory Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada
    Br J Haematol 125:64-8. 2004
    ..Our results indicate that the t(4;14) detected by cIg-FISH is associated with a poor prognosis in MM patients receiving intensive chemotherapy and autotransplant...
  11. ncbi Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma
    C I Chen
    University of Toronto Autologous Blood and Marrow Transplant Programme, The Princess Margaret Hospital, Toronto, Ontario, Canada
    Br J Haematol 113:202-8. 2001
    ..However, our high TRM cautions the use of aggressive therapy, including TBI, in patients over 60 years old...
  12. ncbi Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma
    A D Wechalekar
    Dept of Hematology Oncology, University of Toronto, Princess Margaret Hospital, Toronto, Ont, Canada
    Leuk Lymphoma 44:1147-9. 2003
    ..Thalidomide 200 mg daily with no dose escalation appears as effective and better tolerated than escalated doses for relapsed myeloma patients...